186 related articles for article (PubMed ID: 37202608)
21. Clinical Impact of CYP2C19 Genotype on Clopidogrel-Based Antiplatelet Therapy After Percutaneous Coronary Intervention.
Lee SH; Jeong YH; Hong D; Choi KH; Lee JM; Park TK; Yang JH; Hahn JY; Choi SH; Gwon HC; Jeong MH; Kim BK; Joo HJ; Chang K; Park Y; Ahn SG; Suh JW; Lee SY; Cho JR; Her AY; Kim HS; Kim MH; Lim DS; Shin ES; Song YB;
JACC Cardiovasc Interv; 2023 Apr; 16(7):829-843. PubMed ID: 37045504
[TBL] [Abstract][Full Text] [Related]
22. CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention.
Liu T; Yin T; Li Y; Song LQ; Yu J; Si R; Zhang YM; He Y; Guo WY; Wang HC
Coron Artery Dis; 2014 Aug; 25(5):412-20. PubMed ID: 24608794
[TBL] [Abstract][Full Text] [Related]
23. Association of CYP2C19 Loss-of-Function Alleles with Major Adverse Cardiovascular Events of Clopidogrel in Stable Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention: Meta-analysis.
Biswas M; Kali SK
Cardiovasc Drugs Ther; 2021 Dec; 35(6):1147-1159. PubMed ID: 33523336
[TBL] [Abstract][Full Text] [Related]
24. Clinical Outcomes and Sustainability of Using
Lee CR; Sriramoju VB; Cervantes A; Howell LA; Varunok N; Madan S; Hamrick K; Polasek MJ; Lee JA; Clarke M; Cicci JD; Weck KE; Stouffer GA
Circ Genom Precis Med; 2018 Apr; 11(4):e002069. PubMed ID: 29615454
[TBL] [Abstract][Full Text] [Related]
25. High-Dose Clopidogrel versus Ticagrelor in CYP2C19 intermediate or poor metabolizers after percutaneous coronary intervention: A Meta-Analysis of Randomized Trials.
Sheng XY; An HJ; He YY; Ye YF; Zhao JL; Li S
J Clin Pharm Ther; 2022 Aug; 47(8):1112-1121. PubMed ID: 35396752
[TBL] [Abstract][Full Text] [Related]
26. CYP2C19 phenotype in South-East Asian Acute Coronary Syndrome patients and impact on major adverse cardiovascular events.
Tan DS; Aw JWX; Winther M; Goh LL; Ong HY; Wee E; Liu J; Ho HK
J Clin Pharm Ther; 2020 Feb; 45(1):52-58. PubMed ID: 31670842
[TBL] [Abstract][Full Text] [Related]
27. Ticagrelor Versus Clopidogrel in Patients with Two CYP2C19 Loss-of-Function Alleles Undergoing Percutaneous Coronary Intervention.
Xi Z; Zhou Y; Zhao Y; Liu X; Liang J; Chai M; Yu Y; Liu W
Cardiovasc Drugs Ther; 2020 Apr; 34(2):179-188. PubMed ID: 32140798
[TBL] [Abstract][Full Text] [Related]
28. Genetic Polymorphism of CYP2C19 and Inhibitory Effects of Ticagrelor and Clopidogrel Towards Post-Percutaneous Coronary Intervention (PCI) Platelet Aggregation in Patients with Acute Coronary Syndromes.
Dong P; Yang X; Bian S
Med Sci Monit; 2016 Dec; 22():4929-4936. PubMed ID: 27977637
[TBL] [Abstract][Full Text] [Related]
29. Routine CYP2C19 Genotyping to Adjust Thienopyridine Treatment After Primary PCI for STEMI: Results of the GIANT Study.
Hulot JS; Chevalier B; Belle L; Cayla G; Khalife K; Funck F; Berthier R; Piot C; Tafflet M; Montalescot G;
JACC Cardiovasc Interv; 2020 Mar; 13(5):621-630. PubMed ID: 32139220
[TBL] [Abstract][Full Text] [Related]
30. Clinical Outcomes After Percutaneous Coronary Intervention Over Time on the Basis of CYP2C19 Polymorphisms.
Zhang Y; Zhao X; Ye Y; Li Q; Zeng Y
J Cardiovasc Pharmacol; 2022 Feb; 79(2):183-191. PubMed ID: 34711749
[TBL] [Abstract][Full Text] [Related]
31. Effects of individualized antiplatelet therapy, based on CYP2C19 genotyping, on platelet function in patients underwent percutaneous coronary intervention.
Zhang M; Wang J; Zhang Y; Zhang P; Chao Y; Gao M; Hou Y
Perfusion; 2022 Jan; 37(1):78-85. PubMed ID: 33300437
[TBL] [Abstract][Full Text] [Related]
32. Comparison Between Clopidogrel and Prasugrel Associated With CYP2C19 Genotypes in Patients Receiving Percutaneous Coronary Intervention in a Japanese Population.
Sawayama Y; Yamamoto T; Tomita Y; Asada K; Yagi N; Fukuyama M; Miyamoto A; Sakai H; Ozawa T; Isono T; Hira D; Terada T; Horie M; Nakagawa Y
Circ J; 2020 Aug; 84(9):1575-1581. PubMed ID: 32713878
[TBL] [Abstract][Full Text] [Related]
33. Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance.
Siasos G; Oikonomou E; Vavuranakis M; Kokkou E; Mourouzis K; Tsalamandris S; Zaromitidou M; Kioufis S; Tsigkou V; Deftereos S; Stefanadis C; Tousoulis D
Cardiology; 2017; 137(2):104-113. PubMed ID: 28329746
[TBL] [Abstract][Full Text] [Related]
34. Impact of CYP2C19 polymorphism in prognosis of minor stroke or TIA patients with declined eGFR on dual antiplatelet therapy: CHANCE substudy.
Wu Y; Zhou Y; Pan Y; Zhao X; Liu L; Wang D; Wang C; Li H; Johnston SC; Meng X; Wang Y; Wang Y;
Pharmacogenomics J; 2018 Dec; 18(6):713-720. PubMed ID: 29520080
[TBL] [Abstract][Full Text] [Related]
35. Clopidogrel Pharmacogenetics in Iranian Patients Undergoing Percutaneous Coronary Intervention.
Mahdieh N; Rabbani A; Firouzi A; Zahedmehr A; Hoseinimoghaddam M; Saedi S; Sanati H; Basiri H; Noohi F; Rabbani B; Maleki M
Cardiovasc Toxicol; 2018 Oct; 18(5):482-491. PubMed ID: 29777510
[TBL] [Abstract][Full Text] [Related]
36. Effect of CYP2C19 genetic variants on bleeding and major adverse cardiovascular events in a cohort of Arab patients undergoing percutaneous coronary intervention and stent implantation.
Ali ZO; Bader L; Mohammed S; Arafa S; Arabi A; Cavallari L; Langaee T; Mraiche F; Rizk N; Awaisu A; Shahin MH; Elewa H
Pharmacogenet Genomics; 2022 Jul; 32(5):183-191. PubMed ID: 35389962
[TBL] [Abstract][Full Text] [Related]
37. Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis.
Zhang L; Yang J; Zhu X; Wang X; Peng L; Li X; Cheng P; Yin T
Thromb Res; 2015 Mar; 135(3):449-58. PubMed ID: 25511576
[TBL] [Abstract][Full Text] [Related]
38. Effects of Dual-Dose Clopidogrel, Clopidogrel Combined with Tongxinluo Capsule, and Ticagrelor on Patients with Coronary Heart Disease and CYP2C19*2 Gene Mutation After Percutaneous Coronary Interventions (PCI).
Chen S; Zhang Y; Wang L; Geng Y; Gu J; Hao Q; Wang H; Qi P
Med Sci Monit; 2017 Aug; 23():3824-3830. PubMed ID: 28783717
[TBL] [Abstract][Full Text] [Related]
39. CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations: A systematic review and meta-analysis.
Xi Z; Fang F; Wang J; AlHelal J; Zhou Y; Liu W
Platelets; 2019; 30(2):229-240. PubMed ID: 29257922
[TBL] [Abstract][Full Text] [Related]
40. Impact of the ABCD-GENE Score on Clopidogrel Clinical Effectiveness after PCI: A Multi-Site, Real-World Investigation.
Thomas CD; Franchi F; Keeley EC; Rossi JS; Winget M; David Anderson R; Dempsey AL; Gong Y; Gower MN; Kerensky RA; Kulick N; Malave JG; McDonough CW; Mulrenin IR; Starostik P; Beitelshees AL; Johnson JA; Stouffer GA; Winterstein AG; Angiolillo DJ; Lee CR; Cavallari LH
Clin Pharmacol Ther; 2022 Jul; 112(1):146-155. PubMed ID: 35429163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
